CAR T-cell therapy uses the target specificity of antibody therapy to direct the cytotoxic immune response3

The autologous anti-CD19 CAR T-cell therapy,
TECARTUS®, is individually prepared from each patient’s
T cells in a 6-step process1:

The autologous anti-CD19
CAR T-cell therapy, TECARTUS®,
is individually prepared from each
patient’s T cells in a 6-step process1:

Man next to IV bag.

Leukapheresis

Obtain peripheral blood mononuclear cells

Isolated T­-cells icon.

Selection

Isolate T cells to reduce the likelihood that circulating tumor cells drive the exhaustion of CAR T cells

Anti­-CD3 and anti-­CD28 antibodies + IL-­2 icon.

Activation

Activate T cells using anti-CD3 and anti-CD28 antibodies + IL-2

Anti­-CD19 CAR transgene icon.

Transduction

Insert anti-CD19 CAR transgene

CAR T-­cell expansion icon.

T-cell Expansion

In cell culture, expand the number of CAR T cells to achieve dose

CAR T-­cells in suspension for infusion icon.

Suspension

Formulate CAR T cells into suspension for infusion

CAR=chimeric antigen receptor; CD=cluster of differentiation; IL=interleukin; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024. 2. Data on file. Kite Pharma, Inc; 2022. 3. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(suppl 1):S3-S9.